Regeneron Pharmaceuticals Inc
Latest Regeneron Pharmaceuticals Inc News and Updates

Regeneron's Stock Forecast Is in Question as Omicron Variant Spreads

Is Regeneron's COVID-19 Drug Better Than the Vaccine?

CRISPR Stocks Are Soaring Amid Biotech Breakthrough

Analysts’ Recommendations for United Therapeutics
In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.

A Look at Ionis’s Revenue Streams in the Second Quarter
Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.

Restricted Access Continues to Impact Praluent Sales in 2016
Praluent is one of the Regeneron’s key new additions in the cardiovascular segment. It’s a PCSK9 therapy approved for lowering LDL cholesterol in patients.

Regeneron Continues to Trade at Premium
Regeneron is consistently trading at a premium compared to its peers. As of January 22, it was trading at a valuation multiple of 26.67x its earnings.

Eylea’s Net Sales in the US Jumped in 4Q15, but Was It High Enough?
Eylea, the leading product in Regeneron Pharmaceuticals’s (REGN) portfolio, fetched $746 million during the fourth quarter of 2015 in the US.

Bristol-Myer Squibb’s Opdivo Is Keytruda’s Strong Competitor
the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

A Look at Incyte’s Valuation as of May 25
Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.

Why Eylea Could Face Tough Competition in 2016
In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.

Worst-Case Scenario for Regeneron: What If Eylea Sales Slow Down by 2018?
Regeneron Pharmaceuticals (REGN) depends heavily upon its key drug, Eylea, which recorded global sales of $4.1 billion during fiscal 2015.

What Do Analysts Recommend for United Therapeutics?
23.1% of analysts gave United Therapeutics (UTHR) a “buy” recommendation while 69.2% of analysts rated the company a “hold.”

How Regeneron Is Working to Maintain Eylea’s Dominance
Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011.

Regeneron’s Stock Reacts to Dupilumab Phase 3 Trials
Regeneron Pharmaceuticals (REGN) rose 9.3% during the week ending April 1, 2016.

Understanding Regeneron’s Share Price Movement after Its 4Q15 Results
Regeneron Pharmaceuticals (REGN) earned $1.1 billion in 4Q15, which translates to a 37% YoY (year-over-year) sales growth.

Factors That Will Determine Repatha’s Future Commercial Success
Amgen (AMGN) believes that Repatha will be widely accepted as a major cardiovascular therapy for high-risk patients.

Regeneron’s Dupixent Approved for Atopic Dermatitis
In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.

What Drove Regeneron’s 3Q16 Performance?
In fiscal 3Q16, Regeneron Pharmaceuticals (REGN) recorded revenue amounting to $1.2 billion and net product sales amounting to $857 million.

BioMarin Leads in the Market for Mucopolysaccharidoses Disorders
BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.

Sanofi’s Dupixent: Growth Prospects and Phase 3 Trials
Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.

Dupixent May Be Strong Growth Driver for Sanofi in the Future
Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).

The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug
On October 17, 2016, Teva and Regeneron announced that the FDA had placed the Phase 2 study for fasinumab on clinical hold.

Trump Pushes Regeneron and Eli Lilly Antibodies for COVID-19, Stocks Up

Regeneron to Partner With Roche on COVID-19 Drug

Why Are Most Analysts Recommending a ‘Buy’ for Vertex?
On February 16, 2016, after Vertex’s (VRTX) 4Q15 and fiscal 2015 earnings release, revised ratings showed that 76% of analysts now recommend a “buy” for Vertex stock.

Why Is Vertex Pharmaceuticals’ Valuation at a Discount?
On February 17, 2016, Vertex Pharmaceuticals (VRTX) was trading at a forward PE multiple of 15.20x. It’s trading at a discount when compared to peers Alexion (ALXN) and Regeneron (REGN).

Incyte Was a Star Performer from August 10–17, 2015
By market cap size, Incyte (INCY) is among the top ten holdings of the SPDR S&P Biotech ETF (XBI). Incyte has a weight of 1.22% in XBI’s portfolio.

What Can Investors Expect from Regeneron’s 4Q15 Earnings?
Regeneron will report its earnings for 4Q15 and fiscal 2015 on February 9, 2016. It will report the earnings before the financial markets open in the US.
Amgen has attractive, high-growth assets
The principal products represented 92% of Amgen’s worldwide product sales for the first half of 2014. Total product sales in 3Q14 rose 4% year-over-year, mainly driven by Kyprolis, Prolia, Neulasta, and Xgeva.

What Amgen’s Analysts Recommend in August 2017
Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”

Regeneron Is Down despite Earnings Beat
Regeneron (REGN) reported its Q2 earnings results before the markets opened. REGN reported revenues of $1.93 billion, a YoY increase of 20%.

Analysts Raise Their Target Price for Regeneron in March
Wall Street analysts expect a potential upside of 6.79% for Regeneron Pharmaceuticals based on the company’s closing price on March 27.

What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?
On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.

Understanding Sarepta Therapeutics’ Operational Performance
Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.

Taking Stock of bluebird bio’s Performance
In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

Do Analysts See Any Upside for Regeneron Stock?
Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”

Regeneron Pharmaceuticals’ Gross Margin Trends
In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.

Jazz Pharmaceuticals: Analysts’ View in November
On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9.

Amgen: Analysts’ Recommendations on October 25
Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.

Alkermes in the Third Quarter: A Performance Overview
Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.

Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth
Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.

Biogen: Revenue Growth Is Expected in Q3
Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.

Ionis Pharmaceuticals’ Valuations on September 28
Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.

Ionis Pharmaceuticals’ Stock Performance in September
On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.

Sanofi Eyes Market Expansion with Phase 3 Data for Dupixent
On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.

Shire’s Quarterly Revenue Trend
Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.

What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?
In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.

What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates
Alnylam Pharmaceuticals’ interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.

Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.

What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.

What to Expect from Sarepta’s Second-Quarter Earnings
Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.

Incyte’s Valuations on July 6
Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.

How Ionis Pharmaceuticals’ Valuation Compares
Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.

Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label
On March 19, Regeneron announced positive top line results from its Phase 3 PANORAMA trial.

The Economy Is on a Roll, and It’s Bringing the Stock Market Along With It
Jobs data released this morning shows that the U.S. economy is firing on all cylinders, and the stock market has responded by rallying.

What Led to MEI Pharma Stock’s 55% Rise Last Week?
MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.

Why Regeneron Pharmaceuticals’ Stock Price Fell
Of the 27 analysts tracking Regeneron Pharmaceuticals (REGN) in March, five recommended a “strong buy” and six analysts recommended a “buy.”

How Novartis’s Ophthalmology Business Performed in 2017
In 4Q17, Novartis’s Ophthalmology business generated revenues of $1.35 billion, which reflected ~2% growth on a year-over-year (or YoY) basis and ~2% growth quarter-over-quarter.

Regeneron Pharmaceuticals’ Kevzara, Arcalyst, and Zaltrap
In January 2017, Regeneron Pharmaceuticals’ (REGN) Kevzara was approved in Canada for the treatment of patients with active rheumatoid arthritis.

A Look at Ionis Pharmaceuticals’ January 2018 Valuation
On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.

How’s Incyte’s Valuation in January 2018?
Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.

Pfizer Expects Eucrisa to Report Sales of ~$2.0 Billion
Eucrisa growth trends On December 14, 2016, Pfizer (PFE) announced that it had secured FDA approval for its mild-to-moderate AD (atopic dermatitis) therapy, Eucrisa (crisaborole) 2% ointment, for patients over two years old. This drug was added to Pfizer’s portfolio through the acquisition of Anacor Pharmaceuticals, which was completed in June 2016 for ~$5.2 billion. […]

Inside Novartis’s Ophthalmology Drugs Now
In 3Q17, Novartis’s (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).

Inclisiran: Long-Term Growth Driver for The Medicines Company?
According to a Monte Carlo simulation performed at Harvard, it’s estimated that 5.0 million patients in the United States stand to benefit from PCSK9 inhibitor therapy.

Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis
Launched in US markets in June 2017, Kevzara (sarilumab), Sanofi (SNY) and Regeneron’s (REGN) IL-6 receptor antibody, has received favorable feedback from the physician community.

How Is Novartis’s Lucentis Positioned after 1H17?
In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.

Kevzara May Emerge as a Prominent Rheumatoid Arthritis Drug in 2017
Regeneron and Sanofi have submitted an application seeking regulatory approval for Kevzara in Japan.

Regulatory Approval in Asthma Indication May Boost Dupixent’s Sales
In June 2017 and July 2017, healthcare providers wrote prescriptions for Regeneron (REGN) and Sanofi’s (SNY) Dupixent for 750 new patients on a weekly basis.

Eylea Leads the Retinal Diseases Sector
In 1H17, Eylea’s total sales rose 10% on a year-over-year basis.

Analysts’ Recommendations for Regeneron in September 2017
Of the 26 analysts covering Regeneron Pharmaceuticals in September 2017, seven rated the stock a “strong buy,” six rated it as a “buy,” and 12 rated it as a “hold.” One analyst rated the company as a “strong sell.”

Dupixent and Kevzara: Regeneron’s Long-Term Growth Drivers?
In 2Q17, Regeneron Pharmaceuticals’ (REGN) Dupixent generated revenues of $28.6 million.

What’s Ionis Pharmaceuticals’ Valuation?
Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.

Analysts’ Recommendations for Regeneron in July 2017
In May 2017, Regeneron Pharmaceuticals (REGN) and Inovio Pharmaceuticals (INO) entered into an agreement for an immuno-oncology clinical study.

Dupixent Could Substantially Drive Regeneron’s Growth
In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.

What Drove Biogen Stock in 2Q17?
Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.

The Rise of Amgen Stock in 2Q17
Amgen (AMGN) stock has risen ~5.8% in 2Q17, while it has risen ~17.4% year-to-date as of July 7, 2017.

Eosinophilic Esophagitis: Major Market Opportunity for Dupixent?
Regeneron (REGN) has obtained positive results from its Phase 2 proof-of-concept study evaluating Dupixent in eosinophilic esophagitis.

Dupixent May Prove Effective in Multiple Diseases
Regeneron plans to discuss Dupixent’s innovative mechanism-based treatment approach with regulatory authorities.

Label Expansion May Boost Regeneron’s Dupixent in the Future
Regeneron (REGN) and Sanofi (SNY) are exploring the use of Dupixent in other indications such as asthma, pediatric AD, nasal polyps, and eosinophilic esophagitis.

Dupixent May Be a Major Growth Driver for Regeneron in 2017
After Dupixent’s commercial launch, Regeneron has been involved in creating awareness for the drug among physicians who have been treating AD patients.

Regeneron Continues to Explore Eylea in Multiple New Indications
To further expand Eylea’s label, Regeneron is studying the drug in combination with angiopoietin2 (or Ang2) antibody nesvacumab in two Phase 2 trials.

How Incyte’s Valuation Has Changed since 1Q17 Results
Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.

Amgen’s Repatha Could Gain Market Share in 2017
In 1Q17, Amgen’s (AMGN) Repatha witnessed quarter-over-quarter growth in sales volume of ~14% and 28% in the US and Europe, respectively.

What Could Drive Amgen’s Growth in 2017?
Enbrel, Neulasta, and Epogen are among Amgen’s (AMGN) major revenue-generating drugs, each with annual sales in excess of $1 billion. Enbrel and Neulasta together accounted for ~46% of Amgen’s 2016 revenues.

Dupixent Expected to Be a Solid Addition to Regeneron’s Portfolio
On March 28, 2017, the FDA approved Regeneron (REGN) and Sanofi’s (SNY) Dupixent for the treatment of patients with moderate-to-severe eczema or atopic dermatitis (or AD).

Valeant’s Net Profit Margins Expected to Narrow in 2017
Net profit margins Valeant Pharmaceuticals (VRX) has projected its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) to fall $3.6 billion–$3.7 billion. Besides lower revenue, the company will also have to bear $1.9 billion in cash interest in 2017, which includes $100 million in amortized deferred financing costs. Wall Street analysts have projected that […]

Is Amgen’s Cardiovascular Segment Still a Growth Opportunity?
As cardiovascular diseases cost the global society around $600 billion annually, this segment is a huge growth opportunity for the pharmaceutical industry.

Why United Therapeutics Expects Strong Revenue Growth
United Therapeutics (UTHR) expects to earn revenue exceeding $1.5 billion in 2016. By 2020, the company also expects to surpass its goal of $2 billion in annual revenue.

Valeant Pharmaceuticals Could See Modest Revenue Decline in 2016
In 3Q16, Valeant Pharmaceuticals (VRX) revised its fiscal 2016 revenue guidance downward from $9.9 billion–$10.1 billion to ~$9.6 billion to ~$9.7 billion. In 2016, VRX suffered from talent retention issues, negative press coverage, and litigation.

Dupixent Is Being Explored for Multiple Indications in 2016
In addition to being explored as a monotherapy for AD (atopic dermatitis), Regeneron and Sanofi are also researching Dupixent for other indications.

SOLO 1 and SOLO 2 Trials Could Strengthen Dupixent’s Label
In Phase 3 trials, SOLO 1 and SOLO 2, Regeneron (REGN) and Sanofi (SNY) tested the efficacy of an investigational therapy, Dupixent, compared to a placebo.

Dupixent: Leading Therapy for Atopic Dermatitis in the Future?
Existing treatment options for AD aren’t tolerated well by the entire patient population. Dupixent might become a preferred regimen in the future.

Dupixent Might Help Diversify Regeneron’s Business Model
If Dupixent manages to secure FDA approval, it might have a positive impact on Regeneron’s share prices as well as those of the PowerShares QQQ (QQQ).

Why Neurocrine Biosciences May See Higher Losses in 2016
Wall Street analysts have projected that Neurocrine Biosciences’ net income in 2016 will be -$146.2 million, a significantly higher loss than in 2015.

Why Europe Is an Important Market for Vertex’s Orkambi
Although there are 12,000 eligible patients in Europe who are 12 years and older, Orkambi hasn’t yet received reimbursement approvals for these patients.

Higher Discontinuations Are among Orkambi’s Concerns
Despite a slower launch of the drug in Germany, Orkambi is expected to generate $1 billion–$1.1 billion in 2016.

2016’s Estimated Product Launches: LixiLan, Sarilumab, Lixisenatide
LixiLan indicated for type 2 diabetes is a combination of Lantus and lixisenatide. Lantus is Sanofi’s most frequently prescribed diabetes drug.

Regeneron’s Growth Opportunities: Praluent, Sarilumab, and Dupilumab
Regeneron (REGN) and Sanofi (SNY) have submitted a supplemental BLA to the FDA for review for approving the 300mg monthly dosing of Praluent.

How Significant Is Alexion’s Opportunity with Soliris?
Alexion (ALXN) has been serving the atypical hemolytic uremic syndrome, or aHUS, market for the past five years.